Sanofi draws fire over cost of MS drug LemtradaReutersPARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators. The journal, which published the encouraging results of
...and more »
0 comments:
Post a Comment